Moberg Pharma AB (publ) (MBGPF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Moberg Pharma AB (publ) $0.48, price $1.08, upside -55.6%, quality 35 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Moberg Pharma AB (publ) for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013.
Show more
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
Stock analysis
Moberg Pharma AB (publ) (MBGPF) currently trades at $1.08, while our model-based Fair Value estimate is $0.4800, 55.6% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.
Scenario range: $0.3100 (bear) to $0.5900 (bull), the price of $1.08 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Moberg Pharma AB (publ) reported revenue of 13.5M SEK in FY2025 versus 207K SEK in FY2022, a compound +302.9%/yr. Reported net income was −27.2M SEK in FY2025.
Key figures
Market cap $50.8M · EPS (TTM) $−0.0600 · Return on assets (EBIT) −14.5% · Free cash flow −60.7M SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −56%, MBGPF screens richer than that median.
Fair Value models
Bear $0.3100Fair Value $0.4800Bull $0.5900
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.27/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+38.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+302.9%
’22
’24
’25
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Moberg Pharma AB (publ) with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks
Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score35 · Bottom 25%
Fair Value upside−64.3% · Bottom 25%
Profitability
Return on assets0.0% · Below median
Operating margin (TTM)0.0% · Below median
Growth and dividend
Revenue growth0.0% · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Moberg Pharma AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/MBGPF
Frequently asked questions
Is Moberg Pharma AB (publ) (MBGPF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.4800 versus a price of $1.08, about −56% upside (overvalued).
What is the fair value of MBGPF?
Our model-based fair value for Moberg Pharma AB (publ) is $0.4800 (as of Sep 24, 2026), built from audited fundamentals. The current price: $1.08.
What is the quality score of MBGPF?
Moberg Pharma AB (publ) has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Moberg Pharma AB (publ) (MBGPF)?
Our model-based price target is the fair value of $0.4800 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.3100, optimistic scenario $0.5900. It is a calculation from audited fundamentals, not an analyst target.
What is the Moberg Pharma AB (publ) stock forecast for 2026?
Our models put fair value at $0.4800, about −56% upside versus a price of $1.08 (overvalued). Cautious scenario $0.3100, optimistic scenario $0.5900. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Moberg Pharma AB (publ) (MBGPF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Moberg Pharma AB (publ) it is $0.4800 per share (as of Sep 24, 2026), against a price of $1.08. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Moberg Pharma AB (publ) stock overvalued or undervalued in 2026?
As of Sep 24, 2026, MBGPF trades above its calculated fair value: price $1.08, fair value $0.4800, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MBGPF?
No. The price is what the market pays today ($1.08); the fair value is what the company's own numbers justify ($0.4800). For Moberg Pharma AB (publ) the two are $0.6000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Moberg Pharma AB (publ) worth?
The market values Moberg Pharma AB (publ) at about $50.8M (market capitalisation, as of Sep 24, 2026). Per share that is $1.08; our models calculate a fair value of $0.4800 per share.
What do the bullish and bearish scenarios say about MBGPF?
Our models span a range for Moberg Pharma AB (publ): cautious scenario $0.3100, base $0.4800, optimistic $0.5900 per share (as of Sep 24, 2026, price $1.08). The range comes from different growth and margin assumptions, not from analyst opinions.
Which stocks are comparable to Moberg Pharma AB (publ)?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Moberg Pharma AB (publ) stock attractive at the current price?
The data as of Sep 24, 2026: price $1.08, calculated fair value $0.4800 (−56%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MBGPF calculated?
We run Moberg Pharma AB (publ) through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.4800, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Moberg Pharma AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Moberg Pharma AB (publ) (MBGPF)?
The closing price on Oct 2, 2026 was $1.08. Our model-based fair value is $0.4800, about −56% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Moberg Pharma AB (publ) right now?
The price sits above even our optimistic bull case ($0.5900). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.3100 to $0.5900) leaves room in how you read the outcome.
Key figures of Moberg Pharma AB (publ)
How large is the market capitalisation of Moberg Pharma AB (publ) (MBGPF)?
The market capitalisation of Moberg Pharma AB (publ) is $50.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Moberg Pharma AB (publ) (MBGPF)?
Earnings per share at Moberg Pharma AB (publ) are $−0.0600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Moberg Pharma AB (publ) (MBGPF)?
On an EBIT basis the return on assets of Moberg Pharma AB (publ) is −14.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Moberg Pharma AB (publ) (MBGPF) generate?
The free cash flow of Moberg Pharma AB (publ) is −60.7M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Moberg Pharma AB (publ) in the live analysis
One click puts Moberg Pharma AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026